Profarma posted BRL 3.58 billion revenue: what it means for Profarma stock

Published on 10/16/2026 at 01:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Profarma posted BRL 3.58 billion revenue in the second quarter. Profarma stock's net income reached BRL 70.83 million after a BRL 1.75 million loss.

Quarterly figures and market context

On July 29, 2026, Profarma reported BRL 3.58 billion in second-quarter revenue.
Second-quarter net income was BRL 70.83 million versus a BRL 1.75 million loss in the first quarter.
Profarma stock was last at BRL 9.23 on October 15, 2026 at 5:04 p.m. BRT on B3.

Profarma, BRPFRMACNOR1, Illustration mit AI erstellt.

Profarma posted BRL 3.58 billion in revenue and BRL 0.58 in earnings per share for the second quarter of 2026, according to Investing.com on July 29, 2026. The figures give Profarma stock a concrete earnings anchor even as the latest available market quotation is dated October 15, 2026.

What does the second quarter mean?

The main change was profitability. Profarma reported BRL 70.83 million in net income for the second quarter, compared with a BRL 1.75 million loss in the first quarter. Revenue also increased from BRL 2.87 billion to BRL 3.58 billion between those periods, based on the same results history from Investing.com.

Three reporting milestones

On March 16, 2026, Profarma reported BRL 0.32 in earnings per share for the fourth quarter of 2025. On May 6, 2026, first-quarter earnings per share were negative BRL 0.01. On July 29, 2026, second-quarter earnings per share reached BRL 0.58, marking the latest reported result in the available company timeline.

What does the balance sheet show?

Profarma's June 30, 2026 balance sheet included BRL 487.77 million in cash and BRL 1.90 billion in total debt. Operating cash flow for the second quarter was negative BRL 22.19 million, while net debt stood at BRL 1.41 billion. The figures show that the earnings improvement was accompanied by meaningful financing and working-capital requirements.

Stock valuation and business profile

Profarma distributes pharmaceutical, personal-care and hospital products and also operates retail pharmacies, according to El Fondo. The company is listed on B3 under ticker PFRM3. The quoted 52-week range was BRL 6.11 to BRL 9.70, placing the latest quotation within the upper part of that band.

Market quotation on October 15

On B3, Profarma stock was last at BRL 9.23 on October 15, 2026 at 5:04 p.m. BRT. TradeMap reported a BRL 9.23 close for October 14, 2026 and a 7.12 percent dividend yield in its dated market overview, while the latest quotation gives investors a reference point for the second-quarter earnings comparison.